The best deals are not always the quickest to close, as Teva Pharmaceuticals learned in 2016 after its much-lauded acquisition of Allergan’s generic business, Actavis Generics. In its acquisition of ...

India’s Intas has signed a deal to buy a UK generics business from Teva for £600 million, a sell-off required because of EU competition rules. Teva earlier this year bought the Actavis generics ...

We view Teva's investments as fair. The purchase of Actavis, Allergan's generics business, for $40.5 billion in 2016 destroyed an enormous amount of value, racking up a large amount of debt and ...

Teva has agreed to pay a whopping $1.2 billion to settle a US lawsuit claiming its subsidiary Cephalon paid to hold up generic competition ... subsidiary Solvay and Actavis unit Watson on ...

Teva Pharmaceutical (NYSE ... company's decision to rely heavily on U.S. generics via its $41B buyout of Actavis Generics in 2016. "Upon further reflection and dialogue with management, we believe ...

Get Pro-Level Earnings Insights Before the Market Moves Teva Pharmaceuticals Industries Ltd TEVA has filed a lawsuit contesting the Inflation Reduction Act of 2022, targeting its drug-pricing ...

With more than five dozen generics already tentatively approved for 10 of the drugs selected for the next round of the Medicare Price Negotiation Program, the impact of the negotiations won’t be ...

Saddled with nearly $35 billion in debt since acquiring Allergan's Actavis generic drug business for $40.5 billion, Teva made a series of changes after Kare Schultz joined as its new chief ...

Despite finishing strong across both its innovative and generic businesses in 2024, Teva’s cautious approach to the new year appears to have investors spooked. Teva on Wednesday reported that ...